• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Quick Take: β-Blocker use in pregnancy and the risk of congenital malformations: an international cohort study

byAliya Ramjaun
October 26, 2018
in Cardiology, Chronic Disease, Obstetrics, Pediatrics
Reading Time: 2 mins read
Prenatal antidepressant exposure may increase risk of poor motor development
Share on FacebookShare on Twitter

Beta-blocker medications are commonly used in managing high blood pressure in pregnancy. With an increased prevalence of obesity and related comorbidities in women of reproductive age, exposure to anti-hypertensive medications in early pregnancy has also become more common. The relationship between beta-blocker exposure in utero and the risk of congenital malformations, however, has not been well established. In this cohort study, health registries from the 5 Nordic countries (n=2,310,825) and the US Medicaid database (n=1,358,708) were used to estimate the risks of major congenital malformations associated with first-trimester exposure to beta-blockers in pregnant women with hypertension. Researchers found that women treated with beta-blockers were older than untreated women, more likely to have given birth previously, and were more likely to use anti-hyperglycemic agents. In the US subcohort, women were more likely to smoke and have additional indications for beta-blockers (i.e. migraine, anxiety, arrhythmia, congestive heart failure, ischemic heart disease). The risk of congenital malformations overall was not significantly increased in women using beta-blockers in the first trimester of pregnancy in both the Nordic (RR 1.22, 95% CI 0.88 to 1.71) and US cohorts (RR 1.01, 95% CI 0.80, 1.27). Similar findings were obtained for specific congenital malformations, including cardiac defects and cleft palate. This study was limited due to restricted analysis of live births and exposure based on dispensed medications. Nonetheless, the results of this study indicate that the maternal use of beta-blockers in the first trimester is not associated with a significantly increased risk of congenital malformations.

Click to read the study in Annals of Internal Medicine

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Carvedilol linked to lower cirrhosis complication risk

Beta-blocker use is not associated with better or worse baseline health status in patients with heart failure with preserved ejection fraction

2 Minute Medicine Rewind September 1, 2025

Tags: beta blocker
Previous Post

Quick Take: Use of radiography in patients diagnosed as having acute bronchiolitis in US emergency departments 2007-2015

Next Post

Quick Take: The IRIS Trial: Effect of cricoid pressure compared with a sham procedure in the rapid sequence intubation of anesthesia

RelatedReports

Increasing survival rates for patients with acute liver failure
Gastroenterology

Carvedilol linked to lower cirrhosis complication risk

July 6, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Beta-blocker use is not associated with better or worse baseline health status in patients with heart failure with preserved ejection fraction

January 13, 2026
Imatinib safe and effective as long-term treatment for chronic myeloid leukemia: The IRIS trial
Weekly Rewinds

2 Minute Medicine Rewind September 1, 2025

January 13, 2026
Galcanezumab reduces the frequency of episodic cluster headaches
Neurology

No significant differences between medications for episodic migraine prophylaxis

August 29, 2026
Next Post
General anesthesia may worsen outcomes in endovascular stroke treatment

Quick Take: The IRIS Trial: Effect of cricoid pressure compared with a sham procedure in the rapid sequence intubation of anesthesia

Dementia prevalence declining in the UK

Quick Take: Pre-eclampsia and risk of dementia later in life: nationwide cohort study

Increased diabetes risk observed in gout patients

Quick Take: Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.